HemaBook Chapter 7: How D-dimer in Coagulation Correlates with COVID-19?

D-dimer in COVID-19\r\n

As COVID-19 continues to swipe around the world, rapid diagnosis as well as prognosis and treatment of the COVID-19 patients has become an equally important topic among clinicians. Recently scientists have discovered that COVID-19 has a host cell receptor, Angiotensin Converting Enzyme II^[1] or ACE2. With the help of ACE2, COVID-19 invades the human body rapidly by reproducing on its own at a massive rate, destroying normal cell, tissue and microvascular system, ﬁnally causing acute lung injury, multiple organ failure^[2-4], and intravascular coagulation which occurs in 71.4% of patients who died from COVID-19^[5]. It is widely known that D-dimer is a signiﬁcant bio-marker which correlates with hypercoagulability. More clinical studies have also revealed the relationship between D-dimer and COVID-19.

\r\n

As published on Jama by Zhi Yong’s Group, in the patients’ death(non-survivor) group of novel coronavirus pneumonia, the D-dimer level initially increased as the disease developed, until the 7th day when the D-dimer level broke through the normal range, and ﬁnally plateaued at a high level [Figure 1 A]^[6]. In comparison, the survivor group remained within the normal range consistently. Another article published in the Lancet also claims that there is a close correlation between the D-dimer level and the mortality rate of victims [Figure 1 B]^[7]. The same conclusion was also drawn in Shah’ s research, which utilized a systematic meta-analysis method (including results from 18 articles and a total of 3,682 patients) to draw the forest plots [Figure 1 C, D]^[8]. To sum up, whether in severe or dead COVID-19 patients, the D-dimer level was higher than that which was found in non-severe or surviving patients.

\r\n"}}" id="text-73f986717d" class="8f00b2 cmp-text">

D-dimer in COVID-19

As COVID-19 continues to swipe around the world, rapid diagnosis as well as prognosis and treatment of the COVID-19 patients has become an equally important topic among clinicians. Recently scientists have discovered that COVID-19 has a host cell receptor, Angiotensin Converting Enzyme II^[1] or ACE2. With the help of ACE2, COVID-19 invades the human body rapidly by reproducing on its own at a massive rate, destroying normal cell, tissue and microvascular system, ﬁnally causing acute lung injury, multiple organ failure^[2-4], and intravascular coagulation which occurs in 71.4% of patients who died from COVID-19^[5]. It is widely known that D-dimer is a signiﬁcant bio-marker which correlates with hypercoagulability. More clinical studies have also revealed the relationship between D-dimer and COVID-19.

As published on Jama by Zhi Yong’s Group, in the patients’ death(non-survivor) group of novel coronavirus pneumonia, the D-dimer level initially increased as the disease developed, until the 7th day when the D-dimer level broke through the normal range, and ﬁnally plateaued at a high level [Figure 1 A]^[6]. In comparison, the survivor group remained within the normal range consistently. Another article published in the Lancet also claims that there is a close correlation between the D-dimer level and the mortality rate of victims [Figure 1 B]^[7]. The same conclusion was also drawn in Shah’ s research, which utilized a systematic meta-analysis method (including results from 18 articles and a total of 3,682 patients) to draw the forest plots [Figure 1 C, D]^[8]. To sum up, whether in severe or dead COVID-19 patients, the D-dimer level was higher than that which was found in non-severe or surviving patients.

Application of D-dimer in COVID-19 Prognosis\r\n

According to the study by Zhang’s group, D-dimer among all parameters tested in patients with COVID-19 had the highest C-index, which indicates that it has the highest prediction coincidence rate in routine lab testing methods [Figure 3 A]. In addition, they also found the 2 μg/ml of D-dimer could be the cut-oﬀ value of mortality risk of COVID-19, as DD > 2 μg/ml the survival probability will decrease dramatically [Figure 2 B]. Consequently, they based the evaluation of this value and manifested that when 2 μg/ml was set as the cut-oﬀ value, 92.3% of sensitivity and 83.3% of speciﬁcity is the optimum in all groups [Figure 2 C]^[9].

\r\n

There has been evidence regarding an increased incidence of venous thromboembolic events (VTE) including deep vein thrombosis (DVT) and pulmonary embolism (PE), in patients with severe COVID-19 infection^[9], and D-dimer can also be used as a monitoring indicator of VTE and PE with a cut-oﬀ value of 0.55 μg/ml. Furthermore, Yao not only found that patients with over 2 μg/ml D-dimer needed intensive care and early intervention, but suggested a cut-oﬀ value of 1 μg/ml could help doctors identify patients with a poor prognosis ^[10].

\r\n"}}" id="text-65285011fa" class="8f00b2 cmp-text">

Application of D-dimer in COVID-19 Prognosis

According to the study by Zhang’s group, D-dimer among all parameters tested in patients with COVID-19 had the highest C-index, which indicates that it has the highest prediction coincidence rate in routine lab testing methods [Figure 3 A]. In addition, they also found the 2 μg/ml of D-dimer could be the cut-oﬀ value of mortality risk of COVID-19, as DD > 2 μg/ml the survival probability will decrease dramatically [Figure 2 B]. Consequently, they based the evaluation of this value and manifested that when 2 μg/ml was set as the cut-oﬀ value, 92.3% of sensitivity and 83.3% of speciﬁcity is the optimum in all groups [Figure 2 C]^[9].

There has been evidence regarding an increased incidence of venous thromboembolic events (VTE) including deep vein thrombosis (DVT) and pulmonary embolism (PE), in patients with severe COVID-19 infection^[9], and D-dimer can also be used as a monitoring indicator of VTE and PE with a cut-oﬀ value of 0.55 μg/ml. Furthermore, Yao not only found that patients with over 2 μg/ml D-dimer needed intensive care and early intervention, but suggested a cut-oﬀ value of 1 μg/ml could help doctors identify patients with a poor prognosis ^[10].

In conclusion, D-dimer has enormous clinical values in the treatment and prognosis of COVID-19 as a sensitive monitoring index. In consideration of disordered coagulation micro-environment in patients infected with COVID-19 or at high risk of VTE induced by reduced activity, increased bed time, or in people being quarantined for hospitalization, testing of D-dimer on a regular basis is necessary for rapid monitoring of disease treatment. While a cut-oﬀ value of over 2 ug/ml has been proved by many researchers monitoring patients’ treatment, laboratories are still advised to set their own standard so the variation in demographics can be taken into account.

\r\n

Mindray’s Coagulation D-dimer Solution

\r\n

Mindray’s auto-coagulation analyzers C3100 & C3510 are equipped with both classic mechanical and optical detection mechanisms. The mechanical methodology is insensitive to interference from icteric, lipemic, chylus and hemolytic samples. Moreover, the patented VRIM(VLin-Rate Integrative Method) algorithm has also been developed to combine “Two Point End Method” at a low D-dimer concentration together with “Rate Method” at a higher level [Figure 3]. This has enabled a much wider linearity range of D-dimer results compared with other models on the market [Figure 4].
\r\n

\r\n"}}" id="text-914467b52e" class="8f00b2 cmp-text">

In conclusion, D-dimer has enormous clinical values in the treatment and prognosis of COVID-19 as a sensitive monitoring index. In consideration of disordered coagulation micro-environment in patients infected with COVID-19 or at high risk of VTE induced by reduced activity, increased bed time, or in people being quarantined for hospitalization, testing of D-dimer on a regular basis is necessary for rapid monitoring of disease treatment. While a cut-oﬀ value of over 2 ug/ml has been proved by many researchers monitoring patients’ treatment, laboratories are still advised to set their own standard so the variation in demographics can be taken into account.

Mindray’s Coagulation D-dimer Solution

Mindray’s auto-coagulation analyzers C3100 & C3510 are equipped with both classic mechanical and optical detection mechanisms. The mechanical methodology is insensitive to interference from icteric, lipemic, chylus and hemolytic samples. Moreover, the patented VRIM(VLin-Rate Integrative Method) algorithm has also been developed to combine “Two Point End Method” at a low D-dimer concentration together with “Rate Method” at a higher level [Figure 3]. This has enabled a much wider linearity range of D-dimer results compared with other models on the market [Figure 4].

In addition, Mindray’ s coagulation solution to D-dimer testing is less susceptible to common interferents. As is shown in [Figure 5], when the serum samples are added with bilirubin, hemoglobin, triglycerides and rheumatoid factors at respective concentration, D-dimer results remain at constant levels as before. The Comparison study with Sysmex CS5100 has also shown a good correlation with R2> 97% with interferents added.

\r\n"}}" id="text-1d4e63ae9f" class="8f00b2 cmp-text">

In addition, Mindray’ s coagulation solution to D-dimer testing is less susceptible to common interferents. As is shown in [Figure 5], when the serum samples are added with bilirubin, hemoglobin, triglycerides and rheumatoid factors at respective concentration, D-dimer results remain at constant levels as before. The Comparison study with Sysmex CS5100 has also shown a good correlation with R2> 97% with interferents added.

Mindray’ s D-dimer coagulation reagents are all manufactured in a bottled liquid state which are ready to use [Figure 6], while the majority of coagulation testing kits are made into powder. Simply by opening the cap and loading D-dimer reagents onto the analyzer, preparation can be set up rapidly with ease on Mindray’s coagulation analyzers.

\r\n"}}" id="text-3a54022aa3" class="8f00b2 cmp-text">

Mindray’ s D-dimer coagulation reagents are all manufactured in a bottled liquid state which are ready to use [Figure 6], while the majority of coagulation testing kits are made into powder. Simply by opening the cap and loading D-dimer reagents onto the analyzer, preparation can be set up rapidly with ease on Mindray’s coagulation analyzers.

References：

\r\n

[1] Behl T., Kaur I., Bungau S., Kumar A., Uddin M. S., Kumar C., et al. (2020). The dual impact of ACE2 in COVID-19 and ironical actions in geriatrics and pediatrics with possible therapeutic solutions. Life Sci. 257, 118075. 10.1016/j.lfs.2020.118075.

\r\n

[2] Tian S, Hu W, Niu L, Liu H, Xu H, Xiao SY. Pulmonary pathology of early phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer. J Thorac Oncol. 2020.

\r\n

[3] Chousterman BG, Swirski FK, Weber GF. Cytokine storm and sepsis disease pathogenesis. Semin Immunopathol. 2017;39(5):517–28.

\r\n

[4] Ding YQ, Bian XW. Analysis of coronavirus disease-19 (covid-19). Chin J Pathol. 2020;49(00):E003.

\r\n

[5] Tang N., Li D., Wang X., Sun Z. (2020. b). Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J. Thromb. Haemost. 18, 844–847. 10.1111/jth.14768

\r\n

[6] Dawei Wang, Bo Hu ,et al. Clinical Characteristics of 138 hospitalized patients with 2019 novel Coronavirus-Infected Pneumonia in Wuhan,China[J]. JAMA. 2020.

\r\n

[7] Fei Zhou., MD,a., Ting Yu., MD,b. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 28 March-3 April; 395(10229): 1054–1062.

\r\n

[8] Shah Siddharth., Shah Kuldeep., Patel Siddharth B., Patel Foram S., Osman Mohammed., Velagapudi Poonam., Turagam Mohit K., Lakkireddy Dhanunjaya., Garg Jalaj.(2020). Elevated D-Dimer Levels Are Associated With Increased Risk of Mortality in Coronavirus Disease 2019: A Systematic Review and Meta-Analysis. Cardiol Rev, 28(6), 295-302. doi:10.1097/CRD.0000000000000330

\r\n

[9] Zhang Y, Xiao M, Zhang S, et al. Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N Engl J Med. 2020;382:e38.

\r\n

[10] Simadibrata Daniel Martin., Lubis Anna Mira.(2020). D-dimer levels on admission and all-cause mortality risk in COVID-19 patients: a meta-analysis. Epidemiol Infect, 148(undeﬁned), e202. doi:10.1017/S0950268820002022

\r\n"}}" id="text-45637fd156" class="8f00b2 cmp-text">